Recombinant Human IL-29

Interleukin-29 (IL-29), also known as IFN-λ1, is a cytokine distantly related to type I interferons and the IL-10 family. It exerts its biological effects through a receptor that also binds IL-28A and IL-28B.² This receptor is a heterodimeric class II cytokine receptor that consists of IL-10RB and IL-28RA. IL-29 activities overlap those of type I IFNs and include anti-viral activity and up-regulation of MHC class I antigen expression.³ The expression of IL-29 is induced by virus infection or double-stranded RNA. Upon binding to the receptor, it also induces JAK kinase activation and phosphorylation of STAT and STAT2.⁴ IL-28 and IL-29 have recently been reported to prime dendritic cells to induce proliferation of Foxp3-bearing regulatory T cells.⁵

The biological activity of Human IFN-λ1 was determined in an anti-viral assay using human HepG2 cells infected with encephalomyocarditis.¹ The expected ED₅₀ for this effect is typically 1 - 5 ng/ml.

Histidine Tag

g pvptskpttt gkgchigrfk slspqelasf kkardalees lklknwscss pvfpgnwdlr llqvrerpva leaelaltlk vleaaagpal edvldqplht lhhilsqlqa ciqpqptagp rprgrlhhwl hrlqeapkke sagcleasvt fnlfrlltrd lkyvadgnlc lrtsthpest hhhhhhhhhh

Gly20

Lyophilized

The predicted molecular weight of Recombinant Human IL-29 is Mr 21.4 kDa. However, the actual molecular weight as observed by migration on SDS-PAGE is Mr 26-35 kDa.

21.4

This recombinant protein was 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 with no calcium, magnesium, or preservatives.

This lyophilized protein is stable for six to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution, this protein may be stored at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.

Next Day Ambient

1. Sheppard, P. et al. (2003) Nat Immunol. 4(1):63-8.
2. Zitzmann, K. et al. (2006) Biochem. Biophys. Research Commun. 344:1334
3. Kotenko, SV. et al. (2003) Nat. Immunol. 4:69
4. Maher, SG. et al. (2008) Cancer Biol. Ther. 7:1109
5. Mennechet, F. et al. (2006) Immunobiology 107:4417